Why KKR Financial, Idenix Pharmaceuticals, and iRobot Are Today's 3 Best Stocks

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

It was yet again another day of stronger-than-expected economic data for investors, who took the opportunity to push the broad-based S&P 500 (SNPINDEX: ^GSPC  ) lower on the expectation that the Federal Open Market Committee will take this news as even more reason to begin the tapering of its monthly monetary stimulus.

Two primary reports today pointed to the economy being in better shape than many had projected. First, the Consumer Price Index, a measure of inflation for a similar basket of goods that consumers purchase month to month, was flat in November versus an expected rise of 0.1%. This would signal that inflation is tame on both the business and consumer level, which is great news for consumers looking for an extra reason to spend more this holiday season.

Second, the National Association of Homebuilders index came in with a reading of 58, which was up from 54 last month and higher than economists' expectations. This index is a measure of homebuilder sentiment, and the reading suggests that homebuilders are expecting home prices and sales to flourish in 2014.

Despite this positive news, fear of a somewhat imminent stimulus taper pushed the S&P 500 lower by 5.54 points (-0.31%) to close at 1,781, its fifth day lower in the past six sessions.

Topping the charts and leading all companies higher on the day was KKR Financial (NYSE: KFN  ) which jumped 30.6% after agreeing to be bought out by (get this...) KKR (NYSE: KKR  ) . The all-stock buyout will net KKR Financial shareholders 0.51 shares of KKR common stock upon closing, but the deal itself is a bit odd given that KKR already manages KKR Financial. The deal, according to parent company KKR, will immediately add assets and boost earnings, which sounds great on paper but isn't passing muster with investors who pushed the parent company down on the day.

Shares of Idenix Pharmaceuticals (NASDAQ: IDIX  ) plugged higher by 17.8% after the clinical-stage biopharmaceutical company announced that the U.S. Patent and Trademark Office had declared a patent interference between an Idenix patent and one from Gilead Sciences (NASDAQ: GILD  ) . Within the USPTO's designation, Idenix was declared the senior party and Gilead the junior party. According to USPTO procedures, it's up to the junior party (Gilead) to prove that it developed the patent first. Today's action clearly shows that Idenix's intellectual property could wind up being its saving grace, which is good news since it has struggled mightily to develop its hepatitis C therapeutic pipeline.

Finally, consumer robot manufacturer and Roomba developer iRobot (NASDAQ: IRBT  ) , advanced 17.3% after being upgraded to strong buy from market perform by Raymond James. The company also received a price target of $39, a 25% premium to yesterday's close. Raymond James' covering analyst noted that new product introductions, including the latest Roomba model and a robotic mop known as Braava, should boost sales in 2014. I'm still a bit concerned how budget tightening may hurt iRobot's sales to the government, and, as such, am suggesting you tread cautiously for the time being.

Could this stock be your ticket to top-notch gains in 2014?
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 17, 2013, at 5:49 PM, gilbertfriedman wrote:

    The purported explanation of why Idenix shares rose appears to be wrong. Idenix announced the patent interference on December 9. The increase may be due to the announcement (today) of a phase 2 clinical trial (HELIX-2) in a hcv combination therapy in collaboration with Janssen.

    What kind of standards does Motley Fool have before dissemination information like this?

  • Report this Comment On December 18, 2013, at 3:08 AM, gilbertfriedman wrote:

    Correction: Announcement of enrollment for Helix-2 was on December 2, not December 17. So it cannot explain today's gain any better than the patent announcement on December 9.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2768561, ~/Articles/ArticleHandler.aspx, 9/17/2014 7:37:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement